0000904454-20-000588.txt : 20200820
0000904454-20-000588.hdr.sgml : 20200820
20200820182010
ACCESSION NUMBER: 0000904454-20-000588
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200818
FILED AS OF DATE: 20200820
DATE AS OF CHANGE: 20200820
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Herrmann John A III
CENTRAL INDEX KEY: 0001610928
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-26770
FILM NUMBER: 201121042
MAIL ADDRESS:
STREET 1: C/O NOVAVAX, INC.
STREET 2: 20 FIRSTFIELD ROAD
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NOVAVAX INC
CENTRAL INDEX KEY: 0001000694
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 222816046
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 21 FIRSTFIELD ROAD
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
BUSINESS PHONE: 240-268-2000
MAIL ADDRESS:
STREET 1: 21 FIRSTFIELD ROAD
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2020-08-18
0001000694
NOVAVAX INC
NVAX
0001610928
Herrmann John A III
C/O NOVAVAX, INC.
21 FIRSTFIELD ROAD
GAITHERSBURG
MD
20878
0
1
0
0
EVP, Chief Legal Officer
Common Stock
2020-08-18
4
M
0
1000
50
A
1275
D
Common Stock
2020-08-18
4
M
0
7499
36.6
A
8774
D
Common Stock
2020-08-18
4
M
0
2499
91
A
11273
D
Common Stock
2020-08-18
4
M
0
11249
99.8
A
22522
D
Common Stock
2020-08-18
4
M
0
393
27
A
22915
D
Common Stock
2020-08-18
4
M
0
1952
27
A
24867
D
Common Stock
2020-08-18
4
M
0
13322
27.6
A
38189
D
Common Stock
2020-08-18
4
M
0
8328
46
A
46517
D
Common Stock
2020-08-18
4
S
0
24594
143.92
D
21923
D
Common Stock
2020-08-18
4
S
0
21648
144.79
D
275
D
Stock Option (Right to Buy)
50
2020-08-18
4
M
0
1000
0.0
D
2021-03-10
Common Stock
1000
0.0
D
Stock Option (Right to Buy)
36.6
2020-08-18
4
M
0
7499
0.0
D
2023-03-02
Common Stock
7499
0
D
Stock Option (Right to Buy)
91
2020-08-18
4
M
0
2499
0.0
D
2024-06-12
Common Stock
2499
0
D
Stock Option (Right to Buy)
99.8
2020-08-18
4
M
0
11249
0.0
D
2026-03-15
Common Stock
11249
0
D
Stock Option (Right to Buy)
27
2020-08-18
4
M
0
393
0.0
D
2026-11-14
Common Stock
393
394
D
Stock Option (Right to Buy)
27
2020-08-18
4
M
0
1952
0.0
D
2026-11-14
Common Stock
1952
4298
D
Stock Option (Right to Buy)
27.6
2020-08-18
4
M
0
13322.0
0.0
D
2027-12-15
Common Stock
13322.0
6677.0
D
Stock Option (Right to Buy)
46
2020-08-18
4
M
0
8328
0
D
2028-12-13
Common Stock
8328
11671
D
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.30 to $144.29, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.30 to $145.17, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The shares subject to this option grant vested in four equal annual installments beginning on the first anniversary of the March 10, 2011 grant date.
The shares subject to this option grant vested in four equal annual installments beginning on the first anniversary of the March 2, 2013 grant date.
The shares subject to this option grant vested in four equal annual installments beginning on the first anniversary of the June 12, 2014 grant date.
Twenty-five percent (25%) of the shares subject to this option grant vested on the first anniversary of the March 15, 2016 grant date, and the remaining seventy-five percent (75%) of the shares vested in equal monthly installments over the following three (3) years, subject to continued employment through such vesting date.
Twenty-five percent (25%) of the shares subject to this option grant vested on the first anniversary of the November 14, 2016 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years, subject to continued employment through such vesting date.
Vesting of the shares subject to this option grant is subject to the satisfaction of both (1) a time-based vesting requirement, pursuant to which twenty-five percent (25%) of the shares vested on the first anniversary of the November 14, 2016 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments on the first of each month over the following three (3) years, subject to continued employment through such vesting date, and (2) a performance-based vesting requirement, pursuant to which 33.33%, 33.33%, and 33.34% of the shares vested or will vest if, at any time during the four-year period from the November 14, 2016 grant date, the volume-weighted average stock price of the Company's common stock meets or exceeds $80.00, $120.00, or $160.00, respectively, for twenty (20) consecutive trading days.
Twenty-five percent (25%) of the shares subject to this option grant vested on the first anniversary of the December 15, 2017 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years, subject to continued employment through such vesting date.
Twenty-five percent (25%) of the shares subject to this option grant vested on the first anniversary of the December 13, 2018 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.
/s/ John A. Herrmann III
2020-08-20